Comments
Shares of Natco Pharma today jumped 7.6 per cent as IDFC has initiated coverage of stock with “outperformer’’ rating and a target price of Rs 2,730.
IDFC says that the company is no more just a “generic Copaxone only’’ story.
Copaxone is Teva Pharmaceutical Industries’ top-selling multiple sclerosis drug as US Supreme Court rules for Teva over MS drug patent.
IDFC adds that the generic Hepatitis C drug launch will boost non-US business.
The stock has four “buy’’, one “hold’’ and 1 “sell’’ ratings, according to Thomson Reuters Eikon data.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.